$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hepatobiliary
Hepatobiliary
替诺福韦可使纤维化和肝硬化消退
2025-10-19 11:44:20
Check Details
在研新药可击碎乙肝病毒
2025-10-19 11:44:20
Check Details
慢性乙肝患者肝纤维化的临床预测指标
2025-10-19 11:44:20
Check Details
乙肝替诺福韦停药研究
2025-10-19 11:44:20
Check Details
乙肝治疗:干扰素是否还有一席之地?
2025-10-19 11:44:20
Check Details
乙型肝炎患者禁食是否安全?
2025-10-19 11:44:20
Check Details
乙肝替诺福韦治疗改善生存率
2025-10-19 11:44:20
Check Details
乙肝母婴传播风险随病毒载量增加
2025-10-19 11:44:20
Check Details
乙肝新联合疗法初见成效
2025-10-19 11:44:20
Check Details
肝移植后乙肝防治:专家问答
2025-10-19 11:44:20
Check Details
慢性乙肝患者产后肝炎发作特点及预测因素
2025-10-19 11:44:20
Check Details
3亿乙型肝炎患者,但只有20%接受治疗
2025-10-19 11:44:20
Check Details
1
2
...
99
100
101
102
103
104
105
...
505
506
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Odevixibat: Targeting IBAT to Transform Cholestatic Liver Disease Treatment
2
A Precision FGFR Inhibitor for Cholangiocarcinoma
3
Best time to take Luqu Bopa (Wenkedake) and precautions
4
Is defibrotide included in medical insurance?
5
When was defibrinoside launched on the market?
6
Will defibrination be reimbursed by medical insurance?
7
What conditions is defibrinoside suitable for treating?
8
What is the therapeutic effect of defibrotide?
9
How should defibrinoside be used?
10
What is the effect of defibrotide?
11
Defibrinoside Detailed Instructions
12
What is the effect of defibrination?